Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Geusens

Showing results (81-90 of 147) with videos related to

Pageof 15
Sort By:
Patient Preference and Adherence|February 16, 2013
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosisMickael Hiligsmann, Caroline van Durme, Piet Geusens, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 12, 2018
Assessment of Cortical Interruptions in the Finger Joints of Patients With Rheumatoid Arthritis Using HR-pQCT, Radiography, and MRIMichiel Peters, Astrid van Tubergen, Andrea Scharmga, et al.
Arthritis and Rheumatism|November 13, 2002
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA studyPatrick Garnero, Robert Landewé, Maarten Boers, et al.
Arthritis Care & Research|October 4, 2016
Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled StudyArthur Kavanaugh, Philip J Mease, Andreas M Reimold, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 25, 2018
High Imminent Vertebral Fracture Risk in Subjects With COPD With a Prevalent or Incident Vertebral FractureMayke J van Dort, Piet Geusens, Johanna Hm Driessen, et al.
Therapeutic Advances in Musculoskeletal Disease|November 8, 2019
Balancing benefits and risks in the era of biologicsGiovanni Adami, Kenneth G Saag, Roland D Chapurlat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)Atul A Deodhar, Maxime Dougados, Dominique L Baeten, et al.
Arthritis and Rheumatism|August 31, 2004
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trialThomas J Schnitzer, Jannie Beier, Piet Geusens, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritisLilian H D van Tuyl, Alexandre E Voskuyl, Maarten Boers, et al.
RMD Open|September 1, 2018
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trialPhilip J Mease, Arthur Kavanaugh, Andreas Reimold, et al.
Pageof 15

Showing results (81-90 of 147) with videos related to

Sort By:
Pageof 15
Patient Preference and Adherence|February 16, 2013
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosisMickael Hiligsmann, Caroline van Durme, Piet Geusens, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 12, 2018
Assessment of Cortical Interruptions in the Finger Joints of Patients With Rheumatoid Arthritis Using HR-pQCT, Radiography, and MRIMichiel Peters, Astrid van Tubergen, Andrea Scharmga, et al.
Arthritis and Rheumatism|November 13, 2002
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA studyPatrick Garnero, Robert Landewé, Maarten Boers, et al.
Arthritis Care & Research|October 4, 2016
Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled StudyArthur Kavanaugh, Philip J Mease, Andreas M Reimold, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 25, 2018
High Imminent Vertebral Fracture Risk in Subjects With COPD With a Prevalent or Incident Vertebral FractureMayke J van Dort, Piet Geusens, Johanna Hm Driessen, et al.
Therapeutic Advances in Musculoskeletal Disease|November 8, 2019
Balancing benefits and risks in the era of biologicsGiovanni Adami, Kenneth G Saag, Roland D Chapurlat, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)Atul A Deodhar, Maxime Dougados, Dominique L Baeten, et al.
Arthritis and Rheumatism|August 31, 2004
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trialThomas J Schnitzer, Jannie Beier, Piet Geusens, et al.
Annals of the Rheumatic Diseases|June 8, 2010
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritisLilian H D van Tuyl, Alexandre E Voskuyl, Maarten Boers, et al.
RMD Open|September 1, 2018
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trialPhilip J Mease, Arthur Kavanaugh, Andreas Reimold, et al.
Pageof 15